In a study of syngeneic mouse model, AXL inhibition (cabozantinib/BMS-777607) triggered the awakening of dormant DiDhi 5TGM1-eGFP myeloma cells, as shown by flow cytometric loss of the dye 1,1’-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine (DiD) label, making them more responsive to chemotherapy (187). This evidence concerns the gene AXL and plasma cell myeloma.